Universität zu Köln

Agache, Ioana, Lau, Susanne, Akdis, Cezmi A., Smolinska, Sylwia ORCID: 0000-0001-6736-2696, Bonini, Matteo, Cavkaytar, Ozlem, Flood, Breda, Gajdanowicz, Pawe, Izuhara, Kenji, Kalayci, Omer, Mosges, Ralph, Palomares, Oscar, Papadopoulos, Nikolaos G., Sokolowska, Milena, Angier, Elisabeth, Fernandez-Rivas, Montserrat, Pajno, Giovanni, Pfaar, Oliver, Roberts, Graham C., Ryan, Dermot, Sturm, Gunter J., van Ree, Ronald, Varga, Eva M., van Wijk, Roy Gerth, Yepes-Nunez, Juan Jose ORCID: 0000-0002-9912-0031 and Jutel, Marek (2019). EAACI Guidelines on Allergen Immunotherapy: House dust mite-driven allergic asthma. Allergy, 74 (5). S. 855 - 874. HOBOKEN: WILEY. ISSN 1398-9995

Full text not available from this repository.

Abstract

Allergen immunotherapy (AIT) has been in use for the treatment of allergic disease for more than 100 years. Asthma treatment relies mainly on corticosteroids and other controllers recommended to achieve and maintain asthma control, prevent exacerbations, and improve quality of life. AIT is underused in asthma, both in children and in adults. Notably, patients with allergic asthma not adequately controlled on pharmacotherapy (including biologics) represent an unmet health need. The European Academy of Allergy and Clinical Immunology has developed a clinical practice guideline providing evidence-based recommendations for the use of house dust mites (HDM) AIT as add-on treatment for HDM-driven allergic asthma. This guideline was developed by a multi-disciplinary working group using the Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach. HDM AIT was separately evaluated by route of administration and children and adults: subcutaneous (SCIT) and sublingual AIT (SLIT), drops, and tablets. Recommendations were formulated for each. The important prerequisites for successful treatment with HDM AIT are (a) selection of patients most likely to respond to AIT and (b) use of allergen extracts and desensitization protocols of proven efficacy. To date, only AIT with HDM SLIT-tablet has demonstrated a robust effect in adults for critical end points (exacerbations, asthma control, and safety). Thus, it is recommended as an add-on to regular asthma therapy for adults with controlled or partially controlled HDM-driven allergic asthma (conditional recommendation, moderate-quality evidence). HDM SCIT is recommended for adults and children, and SLIT drops are recommended for children with controlled HDM-driven allergic asthma as the add-on to regular asthma therapy to decrease symptoms and medication needs (conditional recommendation, low-quality evidence).

Item Type:	Journal Article
Creators:	Creators Email ORCID ORCID Put Code Agache, Ioana UNSPECIFIED UNSPECIFIED UNSPECIFIED Lau, Susanne UNSPECIFIED UNSPECIFIED UNSPECIFIED Akdis, Cezmi A. UNSPECIFIED UNSPECIFIED UNSPECIFIED Smolinska, Sylwia UNSPECIFIED orcid.org/0000-0001-6736-2696 UNSPECIFIED Bonini, Matteo UNSPECIFIED UNSPECIFIED UNSPECIFIED Cavkaytar, Ozlem UNSPECIFIED UNSPECIFIED UNSPECIFIED Flood, Breda UNSPECIFIED UNSPECIFIED UNSPECIFIED Gajdanowicz, Pawe UNSPECIFIED UNSPECIFIED UNSPECIFIED Izuhara, Kenji UNSPECIFIED UNSPECIFIED UNSPECIFIED Kalayci, Omer UNSPECIFIED UNSPECIFIED UNSPECIFIED Mosges, Ralph UNSPECIFIED UNSPECIFIED UNSPECIFIED Palomares, Oscar UNSPECIFIED UNSPECIFIED UNSPECIFIED Papadopoulos, Nikolaos G. UNSPECIFIED UNSPECIFIED UNSPECIFIED Sokolowska, Milena UNSPECIFIED UNSPECIFIED UNSPECIFIED Angier, Elisabeth UNSPECIFIED UNSPECIFIED UNSPECIFIED Fernandez-Rivas, Montserrat UNSPECIFIED UNSPECIFIED UNSPECIFIED Pajno, Giovanni UNSPECIFIED UNSPECIFIED UNSPECIFIED Pfaar, Oliver UNSPECIFIED UNSPECIFIED UNSPECIFIED Roberts, Graham C. UNSPECIFIED UNSPECIFIED UNSPECIFIED Ryan, Dermot UNSPECIFIED UNSPECIFIED UNSPECIFIED Sturm, Gunter J. UNSPECIFIED UNSPECIFIED UNSPECIFIED van Ree, Ronald UNSPECIFIED UNSPECIFIED UNSPECIFIED Varga, Eva M. UNSPECIFIED UNSPECIFIED UNSPECIFIED van Wijk, Roy Gerth UNSPECIFIED UNSPECIFIED UNSPECIFIED Yepes-Nunez, Juan Jose UNSPECIFIED orcid.org/0000-0002-9912-0031 UNSPECIFIED Jutel, Marek UNSPECIFIED UNSPECIFIED UNSPECIFIED
URN:	urn:nbn:de:hbz:38-148977
DOI:	10.1111/all.13749
Journal or Publication Title:	Allergy
Volume:	74
Number:	5
Page Range:	S. 855 - 874
Date:	2019
Publisher:	WILEY
Place of Publication:	HOBOKEN
ISSN:	1398-9995
Language:	English
Faculty:	Unspecified
Divisions:	Unspecified
Subjects:	no entry
Uncontrolled Keywords:	Keywords Language ADVERSE SYSTEMIC REACTIONS; SUBLINGUAL IMMUNOTHERAPY; DOUBLE-BLIND; DERMATOPHAGOIDES-PTERONYSSINUS; INTERNATIONAL CONSENSUS; EUROPEAN SURVEY; GLOBAL BURDEN; CHILDREN; EFFICACY; DISEASES Multiple languages Allergy; Immunology Multiple languages
Refereed:	Yes
URI:	http://kups.ub.uni-koeln.de/id/eprint/14897